Annovis Bio Inc Sustainability Reports
Annovis Bio, Inc. is a clinical-stage biotechnology company that develops platform drugs to treat neurodegenerative disorders such as Alzheimer's disease and Parkinson's disease. The company's lead drug candidate, buntanetap, functions by inhibiting multiple neurotoxic proteins to restore axonal transport and brain activity.
Sector: Manufacturing
Country: United States
Exchange: New York Stock Exchange
LEI: 549300IFBVI51FN3NJ32
FIGI: BBG00PN9XDJ4
2 reports from 2021 to 2023
